News

NICE green lights Roche’s Rozlytrek for NTRK tumours
The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from